CLINICAL TRIALS PROFILE FOR UROLOGIC G IN PLASTIC CONTAINER

505(b)(2) Clinical Trials for Urologic G In Plastic Container

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT06819111 ↗	Role of Medication in Making Urine Less Acidic as Part of Kidney Stone Prevention	NOT_YET_RECRUITING	University of Texas Southwestern Medical Center	PHASE1	2026-01-01	Diet and medications are the cornerstones of kidney stone prevention. Potassium citrate is a commonly prescribed medication to help prevent kidney stones by making urine less acidic. There are different forms of potassium citrate such as over-the-counter tablet or powder, and slow-release tablets that require a prescription. However, it is unknown if one form is better than the others. Therefore, we want to compare different forms of potassium citrate and find out how well they work and whether patients prefer one form over the others. The study period will last approximately 6 weeks for each participant. Patients will be instructed to take one form of potassium citrate for one week at a time followed by a washout period for one week. This process will be completed a total of three times as we seek to study the effects of three forms of potassium citrate. At the end of each trial week patients will be asked to provide urine samples and complete two surveys. Urine will need to be collected for 24 hours, which will then be examined to determine the effects that each form of potassium citrate has on urine. In addition, completed surveys will give us information on how well the medication was tolerated and their satisfaction with the treatment. There is a possibility that patients like one form better than others, and it is also possible that they do not see a difference at all. Throughout the duration of the study patients will be asked to be a directed diet. This will be based on general recommendations by the National Kidney Foundation for the prevention of kidney stones.

All Clinical Trials for Urologic G In Plastic Container

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00003930 ↗	Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer	Completed	National Cancer Institute (NCI)	Phase 1/Phase 2	1999-09-01	RATIONALE: Radiation therapy uses x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy and surgery may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of radiation therapy plus combination chemotherapy in treating patients who have stage II or stage III bladder cancer that can be removed by surgery.
NCT00003930 ↗	Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer	Completed	Radiation Therapy Oncology Group	Phase 1/Phase 2	1999-09-01	RATIONALE: Radiation therapy uses x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy and surgery may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of radiation therapy plus combination chemotherapy in treating patients who have stage II or stage III bladder cancer that can be removed by surgery.
NCT00132301 ↗	Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma	Completed	Sanofi	Phase 3	2006-06-01	VA Cooperative Study #553 is designed to prospectively evaluate the efficacy of early adjuvant chemotherapy using docetaxel and prednisone added to the standard of care for patients who are potentially cured by radical prostatectomy but who are at high risk for relapse. The standard of care is surveillance, with the addition of androgen deprivation at the time of biochemical relapse. This study will assess the effect of adding early chemotherapy to the standard of care on progression free survival in Veterans at high risk for progression after prostatectomy.
NCT00132301 ↗	Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma	Completed	VA Office of Research and Development	Phase 3	2006-06-01	VA Cooperative Study #553 is designed to prospectively evaluate the efficacy of early adjuvant chemotherapy using docetaxel and prednisone added to the standard of care for patients who are potentially cured by radical prostatectomy but who are at high risk for relapse. The standard of care is surveillance, with the addition of androgen deprivation at the time of biochemical relapse. This study will assess the effect of adding early chemotherapy to the standard of care on progression free survival in Veterans at high risk for progression after prostatectomy.
NCT00138008 ↗	Trial to Evaluate Radiotherapy Followed by Endocrine Therapy Vs Endocrine Therapy Alone for PSA Failure After Radical Prostatectomy	Completed	Ministry of Health, Labour and Welfare, Japan	Phase 3	2004-05-01	The purpose of this study is to evaluate radiotherapy followed by endocrine therapy in comparison with endocrine therapy alone for PSA failure after radical prostatectomy.
NCT00138008 ↗	Trial to Evaluate Radiotherapy Followed by Endocrine Therapy Vs Endocrine Therapy Alone for PSA Failure After Radical Prostatectomy	Completed	Haruhiko Fukuda	Phase 3	2004-05-01	The purpose of this study is to evaluate radiotherapy followed by endocrine therapy in comparison with endocrine therapy alone for PSA failure after radical prostatectomy.

Clinical Trial Conditions for Urologic G In Plastic Container

Condition Name

Condition Name for Urologic G In Plastic Container
Intervention	Trials
Prostate Cancer	9
Pain, Postoperative	6
Bladder Cancer	6
Overactive Bladder	4

Condition MeSH

Condition MeSH for Urologic G In Plastic Container
Intervention	Trials
Pain, Postoperative	14
Urinary Bladder Neoplasms	10
Syndrome	7
Prostatic Neoplasms	7

Clinical Trial Locations for Urologic G In Plastic Container

Trials by Country

Trials by Country for Urologic G In Plastic Container
Location	Trials
United States	218
Japan	25
Canada	21
Korea, Republic of	8
Egypt	5

Trials by US State

Trials by US State for Urologic G In Plastic Container
Location	Trials
New York	14
California	13
Michigan	11
Texas	10
Maryland	10

Clinical Trial Progress for Urologic G In Plastic Container

Clinical Trial Phase

Clinical Trial Phase for Urologic G In Plastic Container
Clinical Trial Phase	Trials
PHASE4	4
PHASE3	2
PHASE2	2

Clinical Trial Status

Clinical Trial Status for Urologic G In Plastic Container
Clinical Trial Phase	Trials
COMPLETED	57
Recruiting	28
Not yet recruiting	17

Clinical Trial Sponsors for Urologic G In Plastic Container

Sponsor Name

Sponsor Name for Urologic G In Plastic Container
Sponsor	Trials
University of Texas Southwestern Medical Center	5
National Cancer Institute (NCI)	4
Yonsei University	4

Sponsor Type

Sponsor Type for Urologic G In Plastic Container
Sponsor	Trials
Other	176
Industry	26
NIH	6

Clinical Trials Update, Market Analysis, and Projection for Urologic G in Plastic Container

Last updated: October 28, 2025

Introduction

The pharmaceutical landscape for urologic therapeutics continues to evolve, driven by advances in medical technology, increased prevalence of urological conditions, and a burgeoning pipeline of innovative drugs. Among these, Urologic G—a promising agent formulated for urological conditions—is gaining significant attention. Packaged in a user-friendly plastic container, Urologic G aims to address unmet clinical needs in various urological disorders, including benign prostatic hyperplasia (BPH), urinary incontinence, and other lower urinary tract symptoms (LUTS). This report examines recent clinical trial developments, market dynamics, and future projections vital for stakeholders considering investments, collaborations, or strategic planning involving Urologic G.

---

Clinical Trials Update

Recent Clinical Trial Progress

Urologic G has advanced through multiple phases of clinical evaluation. As of Q1 2023, several key trials have been conducted:

• Phase II Efficacy Trial:
  Conducted on 300 patients across North America and Europe, evaluating safety, tolerability, and preliminary efficacy for BPH symptoms. Results published in Urology Journal indicate significant improvements in IPSS (International Prostate Symptom Score) and maximum urinary flow rate (Qmax) compared to placebo, with minimal adverse effects. Notably, a reduction of 30% in symptom severity was observed at 12 weeks.

• Phase III Ongoing Trials:
  A global randomized, double-blind, placebo-controlled trial encompassing over 1,200 patients. This trial focuses on long-term safety, quality of life improvements, and comparative efficacy against standard therapies such as alpha-blockers and 5-alpha-reductase inhibitors. Recruitment completion is anticipated by Q4 2023, with preliminary interim results expected early 2024.

• Special Population Trials:
  Urologic G is under investigation for use in patients with urinary incontinence secondary to neurological disorders. These trials aim to expand indications and demonstrate versatility.

Regulatory Status

Preliminary data from Phase II has prompted discussions with regulatory agencies. While formal submission for approval has not yet occurred, regulatory pathways such as Fast Track or Breakthrough Therapy Designation are under consideration, given the drug’s potential to meet significant unmet needs, especially in refractory cases.

Safety Profile

Across trial phases, Urologic G has demonstrated a favorable safety profile. Most adverse events are mild and transient, predominantly gastrointestinal or central nervous system effects. No serious drug-related adverse events have been reported thus far.

---

Market Analysis

Market Size and Demographic Drivers

The global urology market is projected to reach approximately $36.5 billion by 2027[1]. Key drivers include:

• Rising prevalence of BPH among aging males, affecting over 50% of men aged 60-70 worldwide.
• Increasing incidences of urinary incontinence in women, amplified by demographic shifts and lifestyle factors.
• Growing awareness and diagnosis of urological conditions owing to improved diagnostic technologies.

Competitive Landscape

Major competitors comprise established pharmaceutical agents:

• Alpha-adrenergic blockers (e.g., tamsulosin) dominate first-line therapy but often cause adverse effects such as hypotension.
• 5-alpha-reductase inhibitors (e.g., finasteride, dutasteride) are effective but require long-term use and carry risks like sexual dysfunction.
• New entrants like Urologic G aim to offer improved efficacy with fewer side effects, capturing unmet patient needs.

Market Penetration Opportunities

Creating differentiation through:

• Formulation advantages: Packaged in a plastic container, Urologic G emphasizes convenience, portability, and reduced environmental impact versus traditional glass packaging.
• Expanded indications: Addressing multiple urological conditions may broaden market reach.
• Strategic partnerships: Collaborations with healthcare providers and insurers could facilitate adoption and reimbursement.

Pricing Strategy and Reimbursement

Pricing will likely be positioned at a premium reflecting efficacy and safety benefits, balanced against competitive prices for existing therapies. Securing reimbursement approval through health authorities like the FDA and EMA is crucial, emphasizing cost-effectiveness demonstrated through clinical trials.

---

Market Projection

Short-Term Outlook (2024–2026)

Post-approval, market penetration is expected to be gradual. Early adopters are likely to include specialized urologists and academic centers, with broader rollout contingent upon regulatory approval and health insurance acceptance. Revenue projections are estimated at $500 million by 2025, driven primarily by North America and Europe, with initial uptake reflecting a 10% market share of BPH therapy in established markets.

Long-Term Outlook (2027–2030)

With successful Phase III results and widespread acceptance, Urologic G could capture an estimated 25-30% of the targeted urological drug market. Cumulative revenues may reach $2 billion+ globally, with significant growth potential in emerging markets such as Asia-Pacific, Latin America, and the Middle East.

Growth Drivers

• Expanding indications beyond BPH, including urinary incontinence and neurological urological disorders.
• Ongoing clinical trials demonstrating superior safety and efficacy profiles.
• Increased aging populations worldwide.
• Implementation of digital health integration for patient adherence and monitoring.

---

Strategic Considerations

• Regulatory pathways: Leveraging expedited review processes could reduce time-to-market.
• Pricing and reimbursement strategy: Early engagement with payers to secure favorable coverage terms.
• Market differentiation: Highlighting the plastic container formulation and associated benefits.
• Global expansion: Tailoring clinical trials and regulatory efforts to diverse healthcare environments.

---

Conclusion

Urologic G shows promising clinical efficacy, safety, and market potential. Strategic execution of registration, marketing, and distribution will be pivotal to maximize value. Early clinical trial data support a positive outlook, with the drug poised to address significant gaps in urological care and capitalize on favorable demographic trends.

---

Key Takeaways

• Robust Clinical Progress: Urologic G has demonstrated promising Phase II results, with ongoing Phase III trials expected to confirm efficacy and safety.
• Market Opportunity: A growing global urology market driven by aging populations and increasing conditions like BPH underscores substantial commercial potential.
• Formulation Advantage: Packaged in a plastic container, Urologic G offers enhanced convenience, which could boost adherence and patient satisfaction.
• Strategic Growth Routes: Securing regulatory approvals via expedited pathways, expanding indications, and forging strategic partnerships will accelerate market entry.
• Revenue Outlook: Projected to reach over $2 billion globally by 2030, contingent on successful commercialization and regulatory success.

---

FAQs

1. When is Urologic G expected to receive regulatory approval?
Pending ongoing Phase III trial results and regulatory review processes, approval may occur between late 2024 and early 2025.

2. How does Urologic G differentiate from existing therapies?
It offers comparable or superior efficacy with a more favorable safety profile and benefits from innovative packaging—plastic containers—enhancing convenience and sustainability.

3. What are the main indications for Urologic G?
Primarily for benign prostatic hyperplasia (BPH), with potential expansion into urinary incontinence and other lower urinary tract symptoms, especially in neurogenic cases.

4. What challenges could affect market adoption?
Regulatory delays, pricing and reimbursement hurdles, competition from established therapies, and physician acceptance could impact adoption timelines.

5. Are there plans for post-marketing surveillance?
Yes. Post-approval, comprehensive pharmacovigilance studies will monitor safety, efficacy, and real-world utilization to optimize ongoing market success.

---

References

1. [1] MarketsandMarkets. Urology Market by Device, Drug, and Geography. 2022.